Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Scrip Asks... What Will 2019 Hold For Biopharma? Part 1: Therapeutic Advances

Dec 24 2018

• By Eleanor Malone and Joseph Haas

2019 2018 Perspectives

Related Companies

Amarin Corp plc

Curis, Inc.

BioMarin Pharmaceutical Inc.

Spark Therapeutics, Inc.

Novartis AG

AveXis, Inc.

Genetix Biotherapeutics

Editas Medicine

Allergan plc

CRISPR Therapeutics AG

Vertex Pharmaceuticals Incorporated

Frequency Therapeutics Inc.

AstraZeneca PLC

Eidos Therapeutics, Inc.

Vedanta Biosciences, Inc.

Agendia

Sutro Biopharma, Inc.

Cyclacel Pharmaceuticals, Inc.

Merck & Co., Inc.

Loxo Oncology at Lilly

Navire Pharma, Inc.

Amgen, Inc.

Roche Holding AG

Genentech, Inc.

Regeneron Pharmaceuticals, Inc.

Xencor, Inc.

Merus N.V.

AC Immune SA

Prothena Corporation plc

Biogen, Inc.

Wave Life Sciences Ltd.

Ionis Pharmaceuticals, Inc.

Novo Nordisk A/S

Scinai Immunotherapeutics Ltd.

Novavax, Inc.

ViiV Healthcare

Gilead Sciences, Inc.

Summit Therapeutics Inc.

Polyphor AG

Additional Topics

Innovation Market Intelligence Platform Technologies Research & Development Scrip Asks Cancer Cardiovascular Infectious Diseases Metabolic Disorders BioPharmaceutical

More from Scrip Asks

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window